Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc > NEWS

<< Previous

Bullboard Posts

Next >>

Comment by theshadow39on Mar 14, 2019 10:36am

56 Views

Post# 29484969

RE:RE:NEWS

Redearth Great Points

i couldn’t agree more, the market is surprisingly usually right.

Market Cap is a combination of many factors that are weighted differently in different sectors, notably:

1. IP
2. Assets
3. Current Revenue
4. Industry and potential Industry Growth
5. Forecasted and Potential Blue Sky Revenue Growth

and you are right the farther an industry or stock swings form a current revenue market evaluation model the higher the risk. But investing is always finding a risk/reward balance. With increased risk comes the potential of exponential market cap growth.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading